Adriamycin plus cyclophosphamide in advanced bronchial carcinoma

Area of Science:

• Oncology
• Medical Oncology
• Clinical Cancer Research

Background:

• Advanced lung cancer presents a significant therapeutic challenge.
• Chemotherapy remains a cornerstone in managing advanced lung cancer.
• Exploring effective combination regimens is crucial for improving patient outcomes.

Purpose of the Study:

• To assess the efficacy of Adriamycin plus cyclophosphamide in patients with advanced lung cancer.
• To determine objective response rates and duration of response for this chemotherapy regimen.

Main Methods:

• A cohort of 23 patients with advanced lung cancer received Adriamycin (40 mg/m2 i.v. on day 1) and cyclophosphamide (200 mg/m2 orally, days 1-5).
• Treatment cycles were administered every 3 weeks.
• Patients had no prior chemotherapy, with 5 having received prior radiotherapy.

Main Results:

• Objective improvement was observed in 7 out of 23 patients (30.4%).
• Partial remission was achieved in 3 patients (13.0%).
• The median duration of response was 2 months.

Conclusions:

• The combination of Adriamycin and cyclophosphamide demonstrated activity in advanced lung cancer.
• Further investigation may be warranted to optimize this regimen for improved long-term responses.